


## PDE5/HDAC-IN-1

<b>Cat. No.:</b>	HY-147991
<b>CAS No.:</b>	2414921-48-3
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>29</sub> BrN <sub>4</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	553.45
<b>Target:</b>	Phosphodiesterase (PDE); HDAC; Apoptosis
<b>Pathway:</b>	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage; Epigenetics; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PDE5/HDAC-IN-1 (Compound 26) is a potent phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC <sub>50</sub> values of 46.3 nM and 14.5 nM, respectively. PDE5/HDAC-IN-1 induces cell apoptosis and shows anticancer activities <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	PDE5 46.3 nM (IC <sub>50</sub> )	HDAC6 0.11 μM (IC <sub>50</sub> )	HDAC8 0.12 μM (IC <sub>50</sub> )	HDAC1 2.45 μM (IC <sub>50</sub> )
<b>In Vitro</b>	PDE5/HDAC-IN-1 (Compound 26) shows growth inhibition with IC <sub>50</sub> values of 12.35, 7.19 and 11.79 μM against HT-29, HCT-116 and SW-620 cells, respectively <sup>[1]</sup> . PDE5/HDAC-IN-1 shows cytotoxic activity with IC <sub>50</sub> values of 1.9, 1.5, 2.5, 5.5, 9.8, 18.6, 2 and 28.2 μM against Molt 4, Sup-T1, K562, AGS, PC-3, LNCaP, T47D and CCD966SK, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

### REFERENCES

[1]. ElHady AK, et al. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. Bioorg Chem. 2020 May;98:103742.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA